Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07255846 · ClinicalTrials.gov registry record · Phase 1
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
A Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Terremoto Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07255846 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT) that is actively recruiting participants, run by Terremoto Biosciences. The registered enrollment target is 90 participants, above the 56-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07255846, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT), is actively recruiting participants, sponsored by Terremoto Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TER-1754
Study Locations (1)
Indiana
- Innovative Hematology, Inc. - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07255846
The ClinicalTrials.gov registry entry for NCT07255846 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 56-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (61% higher). The listed sponsor is Terremoto Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07255846 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT07255846 about?
NCT07255846 is a clinical study titled "A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia". This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
What is the current status of trial NCT07255846?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-12-15. Estimated completion is 2028-03.
What conditions does trial NCT07255846 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT07255846?
The interventions under investigation include: Placebo (DRUG), TER-1754 (DRUG).
Who is sponsoring clinical trial NCT07255846?
This trial is sponsored by Terremoto Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07255846 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.